Financial Performance - The company's operating revenue for Q1 2022 was CNY 241,753,611.42, representing a 14.94% increase compared to CNY 210,327,528.92 in the same period last year[3] - The net profit attributable to shareholders decreased by 6.66% to CNY 26,088,609.26 from CNY 27,950,361.13 year-on-year[3] - Total operating costs for Q1 2022 were CNY 202,966,878.11, up 18.76% from CNY 170,860,125.80 in the previous year[23] - Net profit for Q1 2022 was CNY 26,088,609.26, a decrease of 6.68% from CNY 27,950,361.13 in Q1 2021[24] - The total comprehensive income for the first quarter was CNY 26,088,609.26, a decrease from CNY 27,950,361.13 in the previous period, reflecting a decline of approximately 6.7%[26] - Basic and diluted earnings per share for the quarter were CNY 0.2865, down from CNY 0.3069, indicating a decrease of about 7.5%[26] Cash Flow - The net cash flow from operating activities increased by 40.50% to CNY 63,683,424.40, up from CNY 45,327,342.71 in the previous year[3] - Cash inflow from operating activities was CNY 266,992,813.72, compared to CNY 228,458,882.66 in the previous period, representing an increase of approximately 16.9%[27] - Cash flow from financing activities showed a significant increase, with a net cash inflow of CNY 1,176,715,004.05 compared to a cash outflow of CNY 14,420,977.10 in the previous period[29] - The company reported a cash outflow of CNY 203,309,389.32 from operating activities, which was higher than the previous period's outflow of CNY 183,131,539.95[28] - The company has shown a strong increase in cash flow from financing activities, indicating potential for future investments and growth[29] Assets and Liabilities - Total assets at the end of the reporting period reached CNY 2,644,806,040.59, an increase of 86.11% from CNY 1,421,131,071.37 at the end of the previous year[3] - Total liabilities for Q1 2022 amounted to CNY 404,751,959.34, compared to CNY 371,476,863.60 in the previous year[21] - The company's total equity reached CNY 2,240,054,081.25 in Q1 2022, up from CNY 1,049,654,207.77 in Q1 2021[22] Shareholder Information - The total number of common shareholders at the end of the reporting period is 27,613[12] - The largest shareholder, He Wei, holds 19.19% of the shares, amounting to 23,328,753 shares[12] - The company completed its initial public offering, issuing 30.5 million shares, increasing its registered capital from RMB 91,058,824 to RMB 121,558,824[17] - The total number of shares after the IPO is 121,558,824[17] - The company has a total of 92,632,517 restricted shares, with various release dates[16] - The top ten shareholders collectively hold significant stakes, with the top three holding a combined 38.38%[12] - The company has a diverse shareholder base, including both individual and institutional investors[12] Research and Development - Research and development expenses decreased by 38.10% to CNY 16,510.00, attributed to the stabilization study of a product approved in October 2021[8] - Research and development expenses for Q1 2022 were CNY 165,166.61, a decrease from CNY 266,841.99 in Q1 2021[23] Operational Insights - The company experienced a 40.37% increase in accounts payable, reaching CNY 14,433,460.00, due to increased inventory in response to pandemic-related concerns[8] - The net profit decline was influenced by the opening of new subsidiaries, which incurred fixed costs before achieving significant revenue[9] - The company’s cash and cash equivalents increased by 175.67% compared to the previous year, reflecting expanded operational scale and increased cash from stock issuance[8] - The company is focused on expanding its market presence and enhancing shareholder value through strategic initiatives[17]
何氏眼科(301103) - 2022 Q1 - 季度财报